CLINICAL TRIALS, STUDIES, REGISTRIES, DATA

The SERF VT Study is underway in the U.S. at Mayo Clinic, Loyola University Medical Center, and Vanderbilt University Medical Center, and in Canada at Southlake Regional Health Centre, Montreal Heart Institute and Quebec Heart and Lung Institute.

ProActive Study will follow 3,000 kidney transplant patients over a three to five year period to examine the utility of the Prospera donor-derived cell-free DNA (dd-cfDNA) transplant assessment test to accurately identify organ rejection.

The two-year final outcomes from STAR-I trial and six-month results from its European trial STAR-II have been accepted for presentation at the European Glaucoma Society meeting, now postponed to December 2020 following the Covid-19 pandemic.

The study was conducted by Johns Hopkins University and Geisinger and enrolled more than 10,000 women with no prior history of cancer notes Thrive Earlier Detection.

Medtronic Onyx ONE Clear Study met its primary endpoint of cardiac death or myocardial infarction by beating a performance goal derived from contemporary one-month DAPT trials at one-year post-procedure.

The Sense of Touch findings was reported in the prestigious scientific journal, Cell.

TRULO is a prospective, multicenter observational registry study, designed to evaluate post-transplant clinical outcomes in recipients of kidney transplants who are undergoing serial TruGraf testing notes Eurofins.

The supplement, available online now, includes standard and late-breaking abstracts for the American Urological Association (AUA) Annual Meeting.

A new, peer-reviewed case study published in JCO Precision Oncology1 demonstrates the unique ability of Signatera technology to detect esophageal cancer recurrence almost one year before current standards of care, using a simple blood draw to monitor for traces of circulating tumor DNA.